CD274 and neoplasm: The potential efficacy of immunotherapy for locally advanced or metastatic pancreatic NET was reported in the multicohort KEYNOTE-028 study for patients whose tumor had a PD-L1 expression: the ORR was 6.3% (95% CI, 0.2–30.2) [68].